Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310943039> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4310943039 abstract "Patients are often switched between generic formulations of the same drug, but in some cases generic interchangeability is questioned. For generic drugs to be approved, bioequivalence with the innovator drug should be demonstrated, but evidence of bioequivalence is not required in the intended patient population or relative to other approved generics. Aim We aim to identify pathophysiological pharmacokinetic subpopulations for whom there is a difference in comparative bioavailability compared to a healthy population. Methods We used simulated exposures from a nonparametric model of multiple generics and the originator gabapentin. Exposure was simulated for virtual populations with pharmacokinetic characteristics beyond those of healthy subjects with regard to rate of absorption, volume of distribution and reduced renal function. Virtual parallel design bioequivalence studies were performed using a random sample of 24 simulated subjects, with standard acceptance criteria. Results Results indicated increased pharmacokinetic variability for patient populations with a lower rate of absorption or a reduced renal function, but no change in the average comparable bioavailability ratio. This increased variability results in a reduced likelihood of demonstrating bioequivalence. Observations were similar for comparisons between all different formulations, as well as between subjects who received the identical formulation in a repeated fashion. No relevant effect was observed for simulations with increased volume of distribution. Conclusion Our simulations indicate that the reduced likelihood of demonstrating bioequivalence for subjects with altered pharmacokinetics is not influenced by a formulation switch, nor does the average comparable bioavailability ratio change, therefore these results support generic interchangeability and current approval requirements for generics." @default.
- W4310943039 created "2022-12-21" @default.
- W4310943039 creator A5021568119 @default.
- W4310943039 creator A5026635936 @default.
- W4310943039 creator A5040069163 @default.
- W4310943039 creator A5060531026 @default.
- W4310943039 creator A5073316831 @default.
- W4310943039 creator A5090837317 @default.
- W4310943039 date "2023-02-02" @default.
- W4310943039 modified "2023-10-17" @default.
- W4310943039 title "Interchangeability of generic drugs for subpopulations: Bioequivalence simulation from a nonparametric PK model of gabapentin generic drugs" @default.
- W4310943039 cites W2021298363 @default.
- W4310943039 cites W2076039793 @default.
- W4310943039 cites W2093935814 @default.
- W4310943039 cites W2117543856 @default.
- W4310943039 cites W2141163213 @default.
- W4310943039 cites W2152143703 @default.
- W4310943039 cites W2180040121 @default.
- W4310943039 cites W2783406630 @default.
- W4310943039 cites W2959159068 @default.
- W4310943039 cites W3006460095 @default.
- W4310943039 doi "https://doi.org/10.1111/bcp.15629" @default.
- W4310943039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36482842" @default.
- W4310943039 hasPublicationYear "2023" @default.
- W4310943039 type Work @default.
- W4310943039 citedByCount "0" @default.
- W4310943039 crossrefType "journal-article" @default.
- W4310943039 hasAuthorship W4310943039A5021568119 @default.
- W4310943039 hasAuthorship W4310943039A5026635936 @default.
- W4310943039 hasAuthorship W4310943039A5040069163 @default.
- W4310943039 hasAuthorship W4310943039A5060531026 @default.
- W4310943039 hasAuthorship W4310943039A5073316831 @default.
- W4310943039 hasAuthorship W4310943039A5090837317 @default.
- W4310943039 hasBestOaLocation W43109430391 @default.
- W4310943039 hasConcept C102366305 @default.
- W4310943039 hasConcept C105795698 @default.
- W4310943039 hasConcept C112705442 @default.
- W4310943039 hasConcept C139254425 @default.
- W4310943039 hasConcept C181389837 @default.
- W4310943039 hasConcept C199360897 @default.
- W4310943039 hasConcept C2779606619 @default.
- W4310943039 hasConcept C2908647359 @default.
- W4310943039 hasConcept C33923547 @default.
- W4310943039 hasConcept C41008148 @default.
- W4310943039 hasConcept C42404028 @default.
- W4310943039 hasConcept C71924100 @default.
- W4310943039 hasConcept C98274493 @default.
- W4310943039 hasConcept C99454951 @default.
- W4310943039 hasConceptScore W4310943039C102366305 @default.
- W4310943039 hasConceptScore W4310943039C105795698 @default.
- W4310943039 hasConceptScore W4310943039C112705442 @default.
- W4310943039 hasConceptScore W4310943039C139254425 @default.
- W4310943039 hasConceptScore W4310943039C181389837 @default.
- W4310943039 hasConceptScore W4310943039C199360897 @default.
- W4310943039 hasConceptScore W4310943039C2779606619 @default.
- W4310943039 hasConceptScore W4310943039C2908647359 @default.
- W4310943039 hasConceptScore W4310943039C33923547 @default.
- W4310943039 hasConceptScore W4310943039C41008148 @default.
- W4310943039 hasConceptScore W4310943039C42404028 @default.
- W4310943039 hasConceptScore W4310943039C71924100 @default.
- W4310943039 hasConceptScore W4310943039C98274493 @default.
- W4310943039 hasConceptScore W4310943039C99454951 @default.
- W4310943039 hasLocation W43109430391 @default.
- W4310943039 hasLocation W43109430392 @default.
- W4310943039 hasOpenAccess W4310943039 @default.
- W4310943039 hasPrimaryLocation W43109430391 @default.
- W4310943039 hasRelatedWork W1534482532 @default.
- W4310943039 hasRelatedWork W2022148560 @default.
- W4310943039 hasRelatedWork W2022302254 @default.
- W4310943039 hasRelatedWork W2043816944 @default.
- W4310943039 hasRelatedWork W2095722916 @default.
- W4310943039 hasRelatedWork W2108589529 @default.
- W4310943039 hasRelatedWork W2124889282 @default.
- W4310943039 hasRelatedWork W2367063746 @default.
- W4310943039 hasRelatedWork W2588316048 @default.
- W4310943039 hasRelatedWork W2613321035 @default.
- W4310943039 isParatext "false" @default.
- W4310943039 isRetracted "false" @default.
- W4310943039 workType "article" @default.